查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012708

尸检和病理检测市场：按检测类型、检体类型、应用和最终用户划分－2026-2032年全球市场预测

Anatomic Pathology Testing Market by Test Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，尸检病理检测市场价值将达到 479.2 亿美元，到 2026 年将增长至 510 亿美元，到 2032 年将达到 750.1 亿美元，复合年增长率为 6.60%。

主要市场统计数据
基准年 2025 479.2亿美元
预计年份：2026年 510亿美元
预测年份 2032 750.1亿美元
复合年增长率 (%) 6.60%

概述尸检病理检测的发展趋势，包括技术创新、不断变化的临床需求、检查室工作流程和政策因素。

尸检病理学检查处于临床需求与快速技术变革的交汇点，这促使人们对诊断准确性、检测结果报告时间以及与治疗决策的整合提出了新的要求。如今，检查室和诊断服务机构必须在分子表征、免疫分析和影像驱动分析与传统组织学工作流程并存的环境中运作，以支持精准医疗的发展。因此，临床、研究和商业领域的相关人员正在重新思考投资、伙伴关係和营运流程，以应对日益复杂的临床情况，同时控製成本并确保符合监管要求。

对正在重塑诊断流程、资料架构和检查室人员结构的变革性技术、临床和监管变化进行详细检验。

在尸检病理学领域，多项变革正在发生，这些变革正在改变诊断方法、检查室工作流程以及各相关人员之间的资料流。数位病理学的应用正从试点计画逐步过渡到许多机构的生产部署，实现了全切片成像、远端阅片以及演算法影像分析的应用。同时，人工智慧（AI）和机器学习在常规工作流程中的广泛应用，也对诊断演算法的检验、其在临床实践中的应用以及监管核准方面提出了新的考量。

对 2025 年美国关税变化将如何影响供应链、筹资策略、试剂采购和跨境检查室营运进行详细分析。

2025年美国关税政策的发展将对参与尸检病理检测的检查室、製造商和经销商产生复杂而广泛的营运和战略影响。短期内，由于关税导致进口设备、试剂和耗材价格上涨，迫使采购团队重新评估其筹资策略，增加关键试剂的库存缓衝，并加快供应商合格流程，以降低供应中断的风险。因此，采购流程现在通常会加入紧急条款、替代供应商名单和快速检验流程，以确保临床服务的连续性。

透过对测试类型、检体类别、应用程式和最终用户的細項分析，揭示了采用趋势、跨技术协作和优先事项。

按检测类型分析显示，检查室正在建立混合诊断工作流程，将传统组织学方法与新兴的数位和分子诊断技术结合。数位病理学领域正增加对影像分析软体和切片扫描仪的投资，以实现远端阅片和高阶形态计量分析，而苏木精-伊红染色仍是组织评估的基础技术。免疫组织化学在诊断和预测性检测中的作用不断扩大，检查室正根据检测特异性和供应可靠性比较单株抗体和多株抗体策略。分子病理学已成为组织学的核心补充领域。诊断方案结合了萤光原位杂合反应、次世代定序和聚合酵素链锁反应(PCR) 等技术，以捕捉基因组变异和可操作的生物标记。高碘酸雪夫染色、银染和三色染色等特殊染色技术在区分特定诊断和疾病形态方面继续发挥至关重要的作用。

对美洲、欧洲、中东和非洲以及亚太地区的基础设施、偿还、人才和创新采纳的区域性见解。

区域趋势对解剖病理检测技术的应用、部署和运作有显着影响。在美洲，临床检查室和研究机构受益于稳健的资本市场和完善的报销机制，加速了数位病理平台和复杂分子检测的早期应用。随着医疗服务提供者从都市区医疗中心转向区域核心实验室，他们往往优先考虑与肿瘤诊疗路径的整合以及与专业检测中心的合作。

对仪器、试剂和软体公司的竞争策略、创新管道、伙伴关係模式和投资重点进行详细分析。

该行业的企业发展趋势反映了产品专业化、垂直整合和伙伴关係主导扩张的融合。仪器製造商持续投资于自动化和互通性，设计能够与影像分析软体和实验室资讯系统整合的玻片扫描器和检测平台。试剂和抗体供应商透过平衡专有配方和广泛的分销策略，降低临床检查室的单一来源风险，专注于丰富的产品系列和稳定的供应。软体供应商则透过检验的演算法、扩充性的云端架构和以用户为中心的介面来脱颖而出，这些产品和服务支援从常规诊断工作流程到高级研究应用的各种场景。

为检查室管理者、技术开发人员和政策制定者提供实用建议，以加速临床应用、改善营运和增强供应韧性。

检查室负责人应优先考虑数位转型策略，该战略应从概念验证(PoC) 实施开始，并基于明确的检验方案逐步推进至全面运作。从远端二次影像判读或大规模肿瘤病例讨论会等具体用例入手，有助于机构展示临床效用，完善与资讯系统的集成，并在开展更大规模部署之前建立组织信心。同时，采购团队应实施供应商多元化和合格框架，以减少对单一试剂和组件供应商的依赖。这将有助于即使在地缘政治因素或关税波动的情况下也能维持营运的连续性。

对为确保严谨性而采用的调查方法进行简要说明，包括多源资料收集、专家访谈、证据检验验证和分析安全措施。

本研究采用混合方法，强调检验和透明度。首先，透过对同侪审查文献、监管指导文件、已发表的临床研究和公开文件的二次分析，建构了背景基础。然后，透过对实验室负责人、病理科主任、采购主管、技术开发人员和临床终端用户进行结构化访谈等一手定性研究，补充了这些资讯来源，以揭示实际操作情况、检验实践和战略重点。

我们提供综合分析，将技术进步、临床需求、监管压力和营运应对措施联繫起来，从而得出结论并指南相关人员。

总之，解剖病理学生态系统正处于一个关键的十字路口，技术能力与不断变化的临床需求在此交会。数位病理学、先进的免疫组织化学技术和不断扩展的分子诊断技术能够实现更准确、更具指导意义的诊断，但同时，它们也需要协调一致的整合、检验和人才培养策略。监管政策的变化和产业趋势进一步强化了这种环境，在这种环境中，韧性、适应性和实证实践是决定竞争优势和营运差异化的关键因素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：解剖病理学检测市场：依检测类型划分

  • 数位病理学
    • 影像分析软体
    • 幻灯片扫描仪
  • 苏木精-伊红染色
  • 免疫组织化学
    • 单株抗体
    • 多株抗体
  • 分子病理学
    • 萤光原位杂合反应
    • 次世代定序
    • 聚合酵素链锁反应
  • 特殊染色
    • 用高碘酸盐进行希夫染色
    • 银染料
    • 三色染色

第九章：尸检和病理检测市场：检体类型

  • 细胞学检体
  • 冰冻切片
  • 组织切片检查

第十章：尸检和病理检测市场：按应用领域划分

  • 遗传性疾病
    • 染色体异常
    • 单基因疾病
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染疾病
  • 肿瘤学
    • 乳癌
    • 肺癌
    • 摄护腺癌

第十一章：尸检和病理检测市场：按最终用户划分

  • 诊断检查室
  • 医院
  • 研究机构

第十二章：尸检和病理检测市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：尸检病理检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：尸检和病理检测市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国：尸检和病理检测市场

第十六章 中国：尸检和病理检测市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Abcam plc
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company
  • BioGenex Laboratories Inc.
  • Bio SB Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Hamamatsu Photonics KK
  • Hologic Inc.
  • Indica Labs LLC
  • Laboratory Corporation of America Holdings
  • Leica Biosystems
  • Merck KGaA
  • NeoGenomics Laboratories Inc.
  • PerkinElmer Inc.
  • Philips Healthcare
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Sakura Finetek USA Inc.
  • Sonic Healthcare Limited
  • Synlab Holding GmbH
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-436901066173

The Anatomic Pathology Testing Market was valued at USD 47.92 billion in 2025 and is projected to grow to USD 51.00 billion in 2026, with a CAGR of 6.60%, reaching USD 75.01 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.92 billion
Estimated Year [2026] USD 51.00 billion
Forecast Year [2032] USD 75.01 billion
CAGR (%) 6.60%

An introductory overview of anatomic pathology testing trends integrating technological innovation, clinical demand shifts, laboratory workflows, policy drivers

Anatomic pathology testing stands at the intersection of clinical necessity and rapid technological change, driving new expectations for diagnostic accuracy, turnaround time, and integration with therapeutic decision-making. Laboratories and diagnostic services now operate in an environment where molecular characterization, immunoprofiling and image-driven analytics must co-exist with traditional histology workflows to support precision medicine pathways. Consequently, stakeholders across clinical, research and commercial settings are recalibrating investments, partnerships and operational processes to meet rising clinical complexity while controlling costs and ensuring regulatory compliance.

Furthermore, shifts in healthcare delivery-from outpatient oncology programs to centralized reference labs-have altered specimen flows, testing volumes and the locus of diagnostic decision-making. As a result, laboratory leaders are evaluating digital and molecular toolsets not only for their diagnostic value but for their ability to integrate into electronic health records, laboratory information systems and multidisciplinary care teams. In light of these dynamics, the executive synthesis that follows highlights the major drivers reshaping practice, the structural challenges that require strategic response, and the practical considerations that decision-makers should weigh when prioritizing investments in people, technology and partnerships.

A detailed examination of transformative technological, clinical and regulatory shifts reshaping diagnostic pathways, data architecture and laboratory workforce

The landscape of anatomic pathology testing is undergoing several transformative shifts that are changing how diagnoses are made, how laboratories organize work, and how data flows between stakeholders. Digital pathology adoption has progressed from pilot installations to production deployments in many institutions, enabling whole slide imaging, remote review and the application of algorithmic image analysis. At the same time, the diffusion of artificial intelligence and machine learning into routine workflows has introduced new considerations around validation, clinical integration and regulatory clearance of diagnostic algorithms.

Concurrently, molecular pathology techniques such as next-generation sequencing, fluorescence in situ hybridization and targeted PCR are redefining diagnostic categories and therapeutic stratification. This molecular expansion necessitates increased collaboration between histopathology and molecular laboratories, and it elevates demands on bioinformatics, data storage and cross-discipline training. Regulatory attention and reimbursement frameworks are also evolving; as a result, laboratories must navigate changing validation expectations and value demonstration requirements. Lastly, workforce pressures, supply chain volatility and increasing demand for faster turnaround times are prompting laboratories to seek automation, streamlined workflows and strategic vendor partnerships to sustain quality and throughput. Taken together, these shifts are reshaping priorities across procurement, talent development and clinical service design.

A focused analysis of how United States tariff changes in 2025 are altering supply chains, procurement tactics, reagent sourcing and cross-border lab operations

United States tariff policy developments in 2025 have produced a complex set of operational and strategic effects for laboratories, manufacturers and distributors involved in anatomic pathology testing. In the short term, tariff-induced increases on imported instruments, reagents and consumables have compelled procurement teams to reassess sourcing strategies, increase inventory buffers for critical reagents and accelerate supplier qualification processes to reduce exposure to supply disruption. Consequently, procurement cycles now often include contingency clauses, alternative supplier lists and accelerated validation pathways to ensure continuity of clinical services.

Over the medium term, these trade measures have highlighted the economic and logistical value of supplier diversification and regionalized sourcing. Some clinical laboratories and manufacturing partners have pursued nearer-shore manufacturing partnerships, contract manufacturing expansions and localized warehousing to mitigate freight volatility and duty risk. At the same time, manufacturers are revisiting product design and bill-of-materials sourcing to reduce exposure to tariffed components, while service organizations are re-evaluating maintenance and spare parts strategies. Regulatory and contractual implications also surface when suppliers change sourcing origins; therefore, institutions must ensure that any substituted components meet the original performance and regulatory benchmarks.

Moreover, tariff-driven cost pressures can accelerate conversations around automation and assay consolidation that reduce per-test dependency on imported consumables. To manage these pressures, stakeholders increasingly emphasize scenario planning, multi-year supplier agreements with hedging provisions, and collaborative forecasting with supply partners. In sum, tariff dynamics in 2025 are prompting a strategic reorientation toward supply resilience, procurement agility and stronger industry-lab collaboration to safeguard diagnostic continuity.

Segmentation-focused insights across test types, sample categories, applications and end users revealing adoption dynamics, technology linkages and priorities

Analysis by test type reveals that laboratories are balancing legacy histology techniques with emergent digital and molecular modalities to create hybrid diagnostic workflows. Digital Pathology attracts investment in both image analysis software and slide scanners to enable remote review and advanced morphometric analysis, while Hematoxylin and Eosin staining remains the foundational tissue assessment method. Immunohistochemistry continues to expand its role for diagnostic and predictive testing, with laboratories weighing monoclonal versus polyclonal antibody strategies according to assay specificity and supply reliability. Molecular Pathology has become a core complement to histology; diagnostic portfolios blend fluorescence in situ hybridization, next-generation sequencing and polymerase chain reaction approaches to capture genomic alterations and actionable biomarkers. Special Staining techniques such as periodic acid-Schiff stain, silver stain and trichrome stain retain importance for niche diagnostic contexts and for distinguishing disease morphologies.

When sample type is considered, distinctions among cytology samples, frozen sections and tissue biopsy specimens drive differences in pre-analytic handling, turnaround expectations and instrumentation needs. These sample-specific demands in turn shape the workflows and validation strategies laboratories adopt. In terms of application, testing programs align with genetic disorder evaluation, infectious disease detection and oncology diagnostics. Genetic assessments further bifurcate into chromosomal versus single-gene disorder workflows, infectious disease testing delineates bacterial from viral pathogen detection strategies, and oncology protocols increasingly prioritize tumor-specific panels such as those used in breast, lung and prostate cancer contexts. Finally, end users including diagnostic laboratories, hospitals and research institutes have distinct procurement cycles, regulatory requirements and staffing models, all of which influence how technologies are deployed and scaled across care pathways.

Regional insight into infrastructure, reimbursement, talent and innovation adoption distinguishing the Americas, Europe, Middle East & Africa and Asia-Pacific

Regional dynamics exert a strong influence on the adoption, deployment and operationalization of anatomic pathology testing technologies. In the Americas, clinical and research laboratories benefit from robust capital markets and established reimbursement pathways, which facilitate early adoption of digital pathology platforms and complex molecular assays. Transitioning from urban medical centers to regional reference laboratories, providers often emphasize integration with oncology care pathways and partnerships with specialty testing centers.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, reimbursement structures and infrastructure readiness leads to differentiated adoption curves. In parts of Europe, standardized healthcare systems and centralized procurement can support broad rollouts of validated digital workflows, whereas in other regions, variable funding and workforce availability necessitate more focused, incremental implementation strategies. Meanwhile, capacity-building initiatives and public-private partnerships in certain Middle East and African locales are beginning to address gaps in molecular testing and digital infrastructure.

Across Asia-Pacific, a combination of large patient volumes, rapid infrastructure investment and local manufacturing capabilities is accelerating uptake of both high-throughput molecular platforms and automated histology solutions. National strategies that prioritize precision medicine and diagnostic modernization are enabling faster integration of next-generation sequencing, slide scanning and telepathology services. Taken together, these regional patterns underline the need for adaptable deployment models and region-specific commercialization approaches to meet clinical demand and infrastructure realities.

An in-depth view of competitive strategies, innovation pipelines, partnership models and investment priorities among instrumentation, reagent and software players

Company behavior in this sector reflects a mix of product specialization, vertical integration and partnership-driven expansion. Instrumentation manufacturers continue to invest in automation and interoperability, designing slide scanners and laboratory platforms that integrate with image analysis software and laboratory information systems. Reagent and antibody suppliers focus on portfolio breadth and supply stability, balancing proprietary formulations with wider distribution strategies to reduce single-source risk for clinical laboratories. Software vendors are differentiating through validated algorithms, scalable cloud architectures and user-centered interfaces that support routine diagnostic workflows as well as advanced research applications.

Strategic collaboration remains a hallmark of competitive positioning: partnerships among instrument makers, reagent suppliers and software developers enable bundled solutions that shorten adoption cycles and simplify validation efforts for end users. Concurrently, some organizations pursue targeted mergers and acquisitions to accelerate access to complementary capabilities such as bioinformatics, cloud infrastructure or niche assay expertise. Service and support models have grown in importance as laboratories expect robust training, remote troubleshooting and performance guarantees. Finally, firms are increasingly attentive to regulatory pathways and evidence generation, prioritizing clinical validation studies and post-market surveillance to substantiate diagnostic claims and to support payer discussions.

Actionable recommendations for laboratory leaders, technology developers and policymakers to speed clinical adoption, improve operations and boost supply resilience

Laboratory leaders should prioritize a phased digital adoption strategy that begins with proof-of-concept deployments and progresses to scaled production under clear validation protocols. By starting with targeted use cases-such as remote secondary reads or high-volume tumor boards-organizations can demonstrate clinical utility, refine integration with information systems and build institutional confidence before committing to broader rollouts. In parallel, procurement teams should implement supplier diversification and qualification frameworks that reduce reliance on single-source reagents and parts; this will preserve operational continuity in the face of geopolitical or tariff-driven disruption.

Technology developers must invest in interoperable designs and open standards to ease integration with laboratory information systems and electronic health records, thereby lowering the barrier to clinical adoption. Regulatory engagement and transparent performance documentation are essential; developers should pursue rigorous clinical validation and publish peer-reviewed evidence that supports real-world use. Policy makers and payers can accelerate value realization by supporting pilot reimbursement schemes for clinically validated digital and molecular assays that demonstrably improve diagnostic accuracy or patient management.

Finally, workforce planning should combine targeted upskilling with role redesign: pathologists, histotechnologists and molecular specialists require training on new platforms, while organizations should create cross-functional teams that align laboratory scientists, data engineers and clinical stakeholders to operationalize insights into care pathways. These integrated actions will strengthen resilience, optimize resource allocation and enable sustainable adoption.

A concise methodology describing multi-source data collection, expert interviews, evidence triangulation and analytical safeguards applied to ensure rigor

This research applies a mixed-methods approach that emphasizes triangulation and transparency. Secondary analysis of peer-reviewed literature, regulatory guidance documents, published clinical studies and public filings established the contextual foundation. These sources were then augmented by primary qualitative research, including structured interviews with laboratory directors, heads of pathology, procurement executives, technology developers and clinical end users to surface operational realities, validation practices and strategic priorities.

Analytical safeguards included cross-validation of claims against regulatory approvals and published clinical evidence, as well as scenario-based sensitivity checks for operational variables such as turnaround requirements and reagent lead times. Data integrity processes encompassed interview transcription verification, thematic coding to identify convergent insights, and methodical documentation of assumptions and inclusion criteria. Limitations are acknowledged: while primary interviews spanned diverse geographies and institutional profiles, some regional nuance may vary by local policy and reimbursement contexts. Ethical considerations guided the work throughout; interview participants provided informed consent and proprietary information was handled under confidentiality protocols. Together, these methods support a rigorous and auditable synthesis intended to inform practical decision-making.

A concluding synthesis linking technological advances, clinical imperatives, regulatory pressures and operational responses to provide guidance for stakeholders

In conclusion, the anatomic pathology testing ecosystem is at a pivotal juncture where technological capability meets evolving clinical expectations. Digital pathology, advanced immunohistochemistry approaches and expanding molecular diagnostics collectively enable more precise, actionable diagnoses, but they also demand cohesive strategies for integration, validation and workforce development. Regulatory shifts and trade dynamics further contribute to an environment where resilience, adaptability and evidence generation are decisive competitive and operational differentiators.

Therefore, stakeholders should pursue pragmatic, staged adoption pathways, strengthen supplier relationships and invest in interoperable systems that reduce friction across diagnostic workflows. By aligning clinical objectives with robust validation and data governance practices, laboratories can translate technological potential into measurable improvements in diagnostic quality and care coordination. Ultimately, the organizations that balance clinical rigor, operational efficiency and strategic partnerships will be best positioned to deliver sustainable diagnostic value in service of patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anatomic Pathology Testing Market, by Test Type

  • 8.1. Digital Pathology
    • 8.1.1. Image Analysis Software
    • 8.1.2. Slide Scanners
  • 8.2. Hematoxylin And Eosin Staining
  • 8.3. Immunohistochemistry
    • 8.3.1. Monoclonal Antibody
    • 8.3.2. Polyclonal Antibody
  • 8.4. Molecular Pathology
    • 8.4.1. Fluorescence In Situ Hybridization
    • 8.4.2. Next Generation Sequencing
    • 8.4.3. Polymerase Chain Reaction
  • 8.5. Special Staining
    • 8.5.1. Periodic Acid-Schiff Stain
    • 8.5.2. Silver Stain
    • 8.5.3. Trichrome Stain

9. Anatomic Pathology Testing Market, by Sample Type

  • 9.1. Cytology Samples
  • 9.2. Frozen Sections
  • 9.3. Tissue Biopsy

10. Anatomic Pathology Testing Market, by Application

  • 10.1. Genetic Disorders
    • 10.1.1. Chromosomal Disorders
    • 10.1.2. Single Gene Disorders
  • 10.2. Infectious Diseases
    • 10.2.1. Bacterial Infections
    • 10.2.2. Viral Infections
  • 10.3. Oncology
    • 10.3.1. Breast Cancer
    • 10.3.2. Lung Cancer
    • 10.3.3. Prostate Cancer

11. Anatomic Pathology Testing Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Anatomic Pathology Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anatomic Pathology Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anatomic Pathology Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anatomic Pathology Testing Market

16. China Anatomic Pathology Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Abcam plc
  • 17.7. Agilent Technologies Inc.
  • 17.8. Becton, Dickinson and Company
  • 17.9. BioGenex Laboratories Inc.
  • 17.10. Bio SB Inc.
  • 17.11. Danaher Corporation
  • 17.12. Eurofins Scientific SE
  • 17.13. F. Hoffmann-La Roche AG
  • 17.14. Hamamatsu Photonics K.K.
  • 17.15. Hologic Inc.
  • 17.16. Indica Labs LLC
  • 17.17. Laboratory Corporation of America Holdings
  • 17.18. Leica Biosystems
  • 17.19. Merck KGaA
  • 17.20. NeoGenomics Laboratories Inc.
  • 17.21. PerkinElmer Inc.
  • 17.22. Philips Healthcare
  • 17.23. Qiagen N.V.
  • 17.24. Quest Diagnostics Incorporated
  • 17.25. Sakura Finetek USA Inc.
  • 17.26. Sonic Healthcare Limited
  • 17.27. Synlab Holding GmbH
  • 17.28. Sysmex Corporation
  • 17.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 258. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)